1. Introduction {#sec1}
===============

*Achromobacter xylosoxidans*, formerly known as *Alcaligenes xylosoxidans*, is considered a rare cause of bacterial keratitis. Though most cases of *A. xylosoxidans* keratitis resolve with topical antibiotics,[@bib1] there are reported cases where A. xylosoxidans keratitis recurred after initial improvement and required a therapeutic penetrating keratoplasty (PK) for definitive treatment.[@bib2], [@bib3], [@bib4], [@bib5] The detailed clinical history of such severe cases of *A. xylosoxidans* keratitis is not well described in the literature. We report a case of severe *A. xylosoxidans* keratitis with deep involvement of the corneal stroma that spanned a total of 4 months in a patient who had worsening of symptoms despite initial improvement with topical antibiotics and ultimately required therapeutic PK.

2. Case report {#sec2}
==============

A 73 year-old monocular male presented with infectious keratitis of the right eye to his outside ophthalmologist. The left eye had no light perception due to advanced glaucoma. In the right eye, he had advanced glaucoma and had a trabeculectomy and cataract surgery 13 years ago. He was on suppressive oral valacyclovir and topical steroids for presumed herpes simplex virus (HSV) stromal keratitis. He also had some degree of corneal edema and recurrent epithelial defects that had been managed with a bandage contact lens. His baseline vision was 20/70 in this eye. The infectious keratitis was initially managed by his primary ophthalmologist with besifloxacin. He was referred to the Wilmer Eye Institute when he developed a new corneal infiltrate and hypopyon after a month of therapy.

On presentation to Wilmer, the right eye had hand motion vision. Slit lamp examination of the right eye demonstrated a diffusely edematous cornea with three areas of corneal infiltrates, each with indistinct borders, and an overlying epithelial defect measuring 2.5 mm in width and 4 mm in height ([Fig. 1](#fig1){ref-type="fig"}, [Fig. 2](#fig2){ref-type="fig"}). He had a 1.3 mm hypopyon in the anterior chamber. Ophthalmic ultrasonogrophy demonstrated no vitritis to suggest endophthalmitis. Corneal cultures were obtained and hourly fortified vancomycin 25 mg/mL and tobramycin 14 mg/mL were empirically started. Due to his history of herpetic keratitis, treatment dose of oral valacyclovir was started and topical prednisolone was continued at four times a day.Fig. 1Right eye slit lamp photograph -- The slit-lamp exam demonstrates a diffusely edematous cornea with three areas of corneal infiltrates, an overlying epithelial defect measuring 2.5 mm in width and 4 mm in height, and a 1.3 mm hypopyon in the anterior chamber.Fig. 1Fig. 2Right eye slit lamp photograph -- The slit-lamp beam demonstrates the depth of the stromal infiltrate.Fig. 2

Five days later, the culture report revealed *A. xylosoxidans* that had resistance to tobramycin and gentamicin, intermediate susceptibility to ciprofloxacin and cefepime, and susceptibility to ceftazidime, imipenem, meropenem and trimethoprim and sulfamethoxazole.

Based on these sensitivities, fortified vancomycin and tobramycin were discontinued and the patient was started on topical polymyxin B sulfate-trimethoprim and ceftazidime 50 mg/mL. Oral valacyclovir and topical prednisolone was maintained.

Seven days later, the patient could still only see hand motion, but reported subjective improvement. Slit lamp examination demonstrated a resolving epithelial defect of 0.5 × 1 mm, stable infiltrates, and resolution of the hypopyon. The patient continued the antibiotic regimen and followed up with his primary ophthalmologist who was closer to his primary residence.

The patient was seen by his primary ophthalmologist on a weekly basis and compliant with the antibiotic regimen. One month later, his vision had improved to 20/400, which coincided with the resolution of the epithelial defect and a reduction in corneal haze. The antibiotics were discontinued one week later and the patient demonstrated slow clinical improvement at the follow up visit one week later. Two weeks after this visit, the patient was noted to have a recurrent epithelial defect with adjacent corneal infiltrate and a 0.5 mm hypopyon. Topical polymyxin B sulfate-trimethoprim and ceftazidime were restarted.

One week later, the patient returned to Wilmer for reevaluation. Slit lamp examination demonstrated an epithelial defect, diffuse corneal haze, deep stromal infiltrates, and a 1 mm hypopyon. Corneal infiltrates were too deep to culture. He was continued on polymyxin B sulfate-trimethoprim and ceftazidime 50 mg/mL based on previous culture results and susceptibility. Due to the concern for fungal keratitis given long term use of topical steroids, topical voriconazole was added. The treatment for bacterial keratitis was expanded to topical vancomycin and tobramycin. Additionally, oral valacyclovir was maintained and prednisolone was discontinued.

After 20 days on this regimen, the patient had no improvements in the epithelial defect, corneal infiltrates, or hypopyon. He then underwent a therapeutic PK with anterior chamber washout with intracameral injection of ceftazidime, vancomycin, and voriconazole. Cultures from the corneal button yielded moderate *A. xylosoxidans* growth with the same antibiotic susceptibility profile as the first culture. The patient was continued on polymyxin B sulfate-trimethoprim and ceftazidime post-operatively. Two months after the PK, the patient\'s vision improved to 20/150 uncorrected and pinholed to 20/60 and the graft remained clear ([Fig. 3](#fig3){ref-type="fig"}). At his last follow up visit seven months later, his uncorrected vision was 20/40.Fig. 3Right eye slit lamp photograph -- The corneal graft remained clear two months after penetrating keratoplasty.Fig. 3

3. Discussion {#sec3}
=============

*Achromobacter xylosoxidans* is a gram-negative, water-borne organism that typically causes healthcare-associated infections in immunocompromised patients.[@bib6], [@bib7], [@bib8], [@bib9] It is recognized as an emerging pathogen in patients with cystic fibrosis,[@bib10] a cause of bacteremia in cancer patients,[@bib9] and a co-inhabitant in catheter-associated urinary tract infections.[@bib11] *A. xylosoxidans* is a rare cause of ocular infections.

*A. xylosoxidans* can be confused with other nonfermentative, gram-negative rods, especially *Pseudomonas* species due to shared characteristics such as motility and biofilm formation.[@bib12] However, *A. xylosoxidans* has a peritrichous flagella, exhibits a different antibiotic susceptibility profile, and is less virulent than *Pseudomonas*.[@bib13] Because it is less virulent, *A. xylosoxidans* keratitis usually results in a less fulminant clinical course and may cause a delay in patients seeking medical attention.[@bib1]^,^[@bib14] Various risk factors have been described for *A. xylosoxidans* keratitis including previous PK, topical corticosteroids use, and contact lens wear.[@bib1]^,^[@bib2]^,^[@bib14]

Most cases of *A. xylosoxidans* keratitis can be successfully managed with topical antibiotics.[@bib1] The most common empiric antibiotic choices for bacterial keratitis, specifically fluoroquinolones and aminoglycosides, may not be effective against *A. xylosoxidans* keratitis as most *A. xylosoxidans* isolates are highly resistant to ciprofloxacin, gentamicin, and tobramycin.[@bib2] However, when the appropriate topical antibiotic therapy is used, A. xylosoxidans rarely leads to recurrences or a therapeutic PK.[@bib2], [@bib3], [@bib4], [@bib5]

The severity at presentation and clinical course of our patient can be attributed to his numerous risk factors, including chronic topical corticosteroids, HSV stromal keratitis, and contact lens wear, and his delayed presentation that allowed for deep penetration of infection. Despite initial clinical improvement after initiation of treatment with antibiotics guided by susceptibility results, the infection was persistent and resulted in recurrent hypopyon. When the infection did not improve with one month of further topical antibiotic treatment, a therapeutic PK was indicated.

Deep corneal penetration of infectious keratitis complicates management. *A. xylosoxidans* keratitis may result in deep infection through its indolent progression, that predisposes patients to delayed presentation and treatment, or penetration of the cornea, either iatrogenic or through injury. The affected eye of our patient acquired a deep stromal infection through a prolonged clinical course that could not be effectively treated with topical antibiotics. Two documented cases of penetration of the cornea leading to deep infection, a partial thickness corneal laceration and a post-PK eye, exhibited recurrence of infection despite topical antibiotics.[@bib4]^,^[@bib5] Deep infection may result in poor antibiotic penetration, requiring more aggressive management. In the management of deep infectious keratitis refractory to topical antibiotics, intrastromal antibiotic injection may be an alternative to therapeutic PK.[@bib15] This may require repeated injections and was not performed in our patient because of his difficulty in following up due to living over 2 h away from our institution. Furthermore, it is important to note that this organism is often multi-drug resistant and difficult to treat.

4. Conclusions {#sec4}
==============

This report highlights a severe case of *A. xylosoxidans* keratitis with deep involvement of the corneal stroma that could not be treated with topical antibiotics guided by susceptibility results and resulted in a therapeutic PK. The indolent progression of *A. xylosoxidans* keratitis may predispose patients to delayed presentation and delayed treatment. This can result in a deep corneal infection that complicates management through poor antibiotic penetration. Thus, deep infections in *A. xylosoxidans* keratitis warrant the consideration of intrastromal antibiotic injection or early therapeutic PK.
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